Skip to main content
ONCOSIL MEDICAL LTD logo

ONCOSIL MEDICAL LTD — Investor Relations & Filings

Ticker · OSL ISIN · AU000000OSL3 ASX Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2025-12-02 Regulatory Filings
Country AU Australia
Listing ASX OSL

About ONCOSIL MEDICAL LTD

https://www.oncosil.com

OncoSil Medical Ltd is a medical technology company focused on the development and commercialization of localized treatments for patients with unresectable cancers. The company's lead product, OncoSil, is a targeted radioactive isotope microparticle therapy designed to deliver a concentrated dose of beta radiation directly into solid tumors. It is primarily indicated for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. The device utilizes Phosphorus-32 microparticles administered via endoscopic ultrasound-guided fine-needle injection, providing a localized brachytherapy approach intended to reduce tumor volume and improve surgical resectability. OncoSil Medical holds regulatory approvals in multiple jurisdictions, including the CE Mark for use in the European Union and the United Kingdom, and continues to evaluate clinical applications for other solid tumor types.

Recent filings

Filing Released Lang Actions
OSPREY Analysis Shows Survival Benefit for OncoSil Patients 3 pages 287.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 3 December 2025 from OncoSil Medical Limited. It reports interim clinical data from the OSPREY registry, a post-market clinical registry for a medical device used in pancreatic cancer treatment. The content focuses on clinical trial results, survival rates, safety data, and plans for future presentation at a medical congress. There are no financial statements, regulatory certifications, or detailed financial analysis. The document is a public announcement of clinical data and study progress rather than a formal financial or regulatory report. It is not an Annual Report, Interim Report, or Earnings Release. It is also not a Management Report or Investor Presentation. The document is a regulatory announcement informing the market about clinical data and upcoming presentations, fitting best under Regulatory Filings (RNS).
2025-12-02 English
Change of Director's Interest Notice x3 6 pages 366.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including shares and options acquired or disposed of, nature of interests, and consideration. The document is a formal notification of personal share transactions by company directors. It does not contain financial statements or company performance data but focuses on insider share dealings by directors. Therefore, it fits the definition of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a report publication notice but a detailed insider transaction report.
2025-12-01 English
Application for quotation of securities - OSL 6 pages 19.2KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of new securities (shares) to directors as payment for director fees, with references to prior shareholder approval at the 2025 AGM. The document is an announcement of the quotation of securities rather than a report containing financial statements or detailed financial analysis. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory certification or legal proceeding. The document fits best into the category of Share Issue/Capital Change (SHA) as it announces the issuance and quotation of new shares to directors.
2025-11-30 English
Notification regarding unquoted securities - OSL 8 pages 25.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted options to directors of Oncosil Medical Ltd. It includes specifics such as the number of securities issued, exercise prices, expiry dates, and references to ASX listing rules, particularly Listing Rule 10.11 and 7.2. The document is a formal notification to the ASX about the issue of new unquoted securities (options) as equity incentives to directors, which is a capital change event. There is no financial performance data, earnings information, or management discussion. The document is not a report but an announcement of a securities issuance event. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (9352 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2025-11-30 English
Notification of cessation of securities - OSL 4 pages 15.0KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of certain securities (options) for ONCOSIL MEDICAL LTD. It provides specifics about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. This is a regulatory announcement related to changes in the company's securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an official notification of changes in securities. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-11-20 English
Final Director's Interest Notice 2 pages 282.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's cessation date and securities interests, including options and shares held by the director and related parties. The content focuses on personal share transactions and interests of a director rather than financial results, management changes, or other report types. The document length is short (2520 characters), and it is a formal notification of director's share interests, consistent with insider trading or director dealing disclosures. Therefore, the document fits the category of Director's Dealing (DIRS).
2025-11-20 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.